Mirum Pharmaceuticals, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.34M19.14M77.06M186.37M336.89M
Cost of Revenue 12.37M47.04M81.64M
Gross Profit -0.34M19.14M64.69M139.34M255.25M
Operating items
Research & Development 42.99M81.61M131.43M106.84M102.61M140.63M
Selling, General & Administrative 11.75M22.69M59.22M89.07M145.88M202.22M
Other Operating Expenses 1.90M12.37M47.04M81.64M
Operating Expenses 54.74M104.30M192.55M208.28M295.53M424.49M
Operating Income -54.74M-104.30M-173.41M-131.22M-109.15M-87.61M
EBIT -54.74M-104.30M-173.41M-131.22M-109.15M-87.61M
Non-operating items
Interest & Investment Income 2.23M1.56M0.37M3.86M13.73M13.79M
Other Non Operating Income -0.02M-0.19M-0.58M0.36M-49.08M1.21M
Non Operating Income -0.02M-0.19M-0.58M0.36M-2.82M1.21M
Net income details
EBT -52.65M-103.37M-84.22M-142.07M-162.42M-86.91M
Tax Provisions 0.02M0.01M0.04M-6.41M0.99M1.03M
Profit After Tax -52.55M-103.27M-83.99M-135.66M-163.41M-87.94M
Income from Continuing Operations -52.67M-103.38M-84.25M-135.66M-163.41M-87.94M
Consolidated Net Income -52.67M-103.38M-84.25M-135.66M-163.41M-87.94M
Income towards Parent Company -52.67M-103.38M-84.25M-135.66M-163.41M-87.94M
Net Income towards Common Stockholders -52.67M-103.38M-84.25M-135.66M-163.41M-87.94M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 22.99M25.72M30.64M36.87M46.61M48.00M
Shares Outstanding (Diluted Average) 33.98M40.89M47.52M
EBITDA -54.74M-104.30M-173.41M-131.22M-109.15M-87.61M
Tax Rate 4.51%